Efficacy and safety of ciprofloxacin, eye ointment and eye drops, 0.3 %, in modern therapy of infectious and inflammatory eye diseases. A review

Bacterial conjunctivitis is the main reason for patients to visit ophthalmologists, and the incidence is high among both children and adults. In the current version of the Clinical Guidelines for the section “Conjunctivitis”, approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation, antibacterial and antiseptic agents are recommended as etiotropic therapy for the treatment of infectious conjunctivitis (bacterial, chlamydial) or in case of suspicion/prevention of secondary bacterial infection in conjunctivitis of other etiologies with antibacterial purposes. Antibacterial agents in the dosage form of eye drops are represented by the following International Nonproprietary Names (INN): ofloxacin, ciprofloxacin, levofloxacin, moxifloxacin, netilmicin, tobramycin, chloramphenicol, in the dosage form of eye ointments: INN tetracycline, erythromycin, tetracycline + chloramphenicol. Of the antiseptic agents, eye drops are presented with the INN picloxidine and benzyldimethyl-myristoylamino-propylammonium. Thе review presents the comparative efficacy and safety of ciprofloxacin eye drops and ointment, as well as on the assessment of their clinical significance in the treatment of bacterial eye infections.

1. Clinical guidelines “Conjunctivitis” (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/629_2

2. Hobden JA, O’Callaghan RJ, Insler MS, Hill JM. Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. Cornea. 1993 Mar; 12 (2): 138–41. doi: 10.1097/00003226-199303000-00008

3. Lin A, Rhee MK, Akpek EK, et al. American Academy of Ophthalmology preferred practice pattern cornea and external disease panel. Bacterial Keratitis Preferred Practice Pattern®. Ophthalmology. 2019 Jan; 126 (1): P1–P55.

4. Babushkin A.E., Shrvchuk N.E. Bacterial conjunctivitis (literature review). Point of View. East–West. 2021; 3: 87–90 (In Russ.). https://doi.org/10.25276/2410-1257-2021-3-87-90

5. Hyndiuk RA, Skorich DN, Davis SD, et al. Fortified antibiotic ointment in bacterial keratitis. Am J Ophthalmol. 1988 Mar 15; 105 (3): 239–43. doi: 10.1016/0002-9394(88)90002-5

6. Lomholt JA, Møller JK, Eh lers N. Prolonged persistence on the ocular surface of fortified gentamicin ointment as compared to fortified gentamicin eye drops. Acta Ophthalmol. Scand. 2000; 78 (1): 34–6. doi: 10.1034/j.1600-0420.2000.078001034.x

7. Hashemi K, Chuang AZ, Schweitzer C, Lanier JD. Comparison of antibiotic drops placed in the conjun ctival cul-de-sac to antibiotic ointment applied to the lid margin in reduction of bacterial colonization on the lid margin. Cornea. 2000 Jul; 19 (4): 459–63. doi: 10.1097/00003226-200007000-00010

8. Li X, Liu L, Deng Y, et al. Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects. Drug Dev Ind Pharm. 2020 Sep; 46 (9): 1487–94. doi: 10.1080/03639045.2020.1810263

9. Zhou J.S. Ofloxacin content in tears following topical use of 0.3 % ointment. Zhonghua Yan Ke Za Zhi Chin. J. Ophthalmol. 1991; 27 (2): 115–7.

10. Egorov A.E. Ofloxacin 0.3 % ophthalmological solution and eye ointment in today treatment of inflammatory and infectious eye diseases. Literary review. RMZh. Klinicheskaya oftal’mlogiya. 2012; 13 (3): 114–7 (In Russ.).

11. Galeeva G.Z., Rascheskov A.Yu. The therapy of inflammatory diseases of the anterior segment and the adnexa of children in the light of modern ideas on multiple drug resistance of pathogens. Russian ophthalmological journal. 2017; 10 (2): 87–90 (In Russ.). doi: 10.21516/2072-0076-2017-10-2-87-90

12. Product monograph Cipromed, eye drops 0.3 %. (Sentiss Pharma, Registration code: П N012981/01 (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=620d64ae-fc62-439b-b0d94dd161df0bfc (accessed: 02.12.2024)

13. Product monograph Oftocipro. (JSC «Tatchempharmpreparaty», Registration code: ЛП-№(001649)-(РГ-RU) (In Russ.). Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=eb894369-959f-4d6a-9ec5e7b223152893 (accessed: 02.12.2024)

14. Petrov S.Yu., Safonova D.M. Ophthalmic preservatives: from benzalkonium chloride to polyquaternium. Literature review. RMZh. Klinicheskaya oftal’mlogiya. 2014; 14 (2): 97–108. (In Russ.).

15. Galeeva G.Z., Rascheskov A.Yu. Oftocipro eye ointment in the combined treatment of keratitis in children. Russian ophthalmological journal. 2015; 8 (4): 38–41 (In Russ.).

16. Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022 Feb; 36 (2): 361–8. doi: 10.1038/s41433-021-01668-x

17. Azari AA, Arabi A. Conjunctivitis: A systematic review. J Ophthalmic Vis Res. 2020; 15 (3): 372–95. doi: 10.18502/jovr.v15i3.7456

18. Trubilin V.N. Therapeutic ophthalmology and diseases of the ocular surface: A textbook. Moscow: FMBA, 2023 (In Russ.).

19. Drago L. Topical antibiotic therapy in the ocular environment: The benefits of using Moxifloxacin eyedrops: 4. Microorganisms. Multidisciplinary Digital Publishing Institute. 2024; 12 (4): 649. doi: 10.3390/microorganisms12040649

20. Oikonomakou M-Z, Makri OE, Panoutsou E, et al. Bacteriology and antimicrobial susceptibility patterns of childhood acute bacterial conjunctivitis in Western Greece. Med. Hypothesis Discov. Innov. Ophthalmol. J. 2019; 8 (4): 266–71. PMID: 31788487

21. Khor W-B, Lakshminarayanan R, Periayah MH, et al. The antibiotic resistance profiles of Pseudomonas aeruginosa in the Asia Cornea Society Infectious Keratitis Study. Int Ophthalmol. 2024; 44 (1): 361. doi: 10.1007/s10792-024-03270-y

22. Chatterjee S, Agrawal D, Gomase SN, et al. Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020. Indian J. Ophthalmol. 2022; 70 (12): 4391–8. doi: 10.4103/ijo.IJO_1033_22

23. Cabrera-Aguas M, Chidi-Egboka N, Kandel H, Watson SL. Antimicrobial resistance in ocular infection: A review. Clin Exp Ophthalmol. 2024 Apr; 52 (3): 258–5. doi: 10.1111/ceo.14377

24. Lomholt JA, Kilian M. Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol. 2003; 87 ( 10): 1238–40. doi: 10.1136/bjo.87.10.1238

25. Aramă V. Topical antibiotic therapy in eye infections — myths and certainties in the era of bacterial resistance to antibiotics. Romanian J Ophthalmol. 2020; 64 (3): 245–60.

26. Vorontsova T.N., Popov V.Y., Shaporova V.J. Minimal inhibitory concentrations of modern topical antimicrobials. Ophthalmology. 2014; 11 (3): 68–73. (In Russ.). doi: 10.18008/1816-5095-2014-3-68-73

27. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3 % ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. Arch. Ophthalmol. 1993; 111 (9): 1210–8. doi: 10.1001/archopht.1993.01090090062020

28. Abdulaeva A.E., Amiriov A.N., Sajfullina F.R. Using Oftocipro in the treatment of infectious and inflammatory diseases of the anterior segment of the eye. Russian ophthalmological journal, 2013; 6 (2): 101–3 (In Russ.).

29. Trubilin V.N., Polunina E.G., Angelova D.V., et al. The antibacterial eye ointments in the treatment of eyelids and conjunctiva acute and chronic diseases. Ophthalmology. 2019; 16 (1): 31–7 (In Russ.). https://doi.org/10.18008/1816-5095-2019-1-31-37

30. Trubilin V.N., Polunina E.G., Kozhukhov A.A., et al. Medical therapy for conjunctivitis. Literature review. The EYE. 2023; 25 (3): 225–33 (In Russ.). https://doi.org/10.33791/2222-4408-2023-3-225-233

31. Trubilin V.N., Poluninа E.G., Andzhelova D.V., et al. The treatment algorithm for meibomyitis, hordeolum and halazion. Ophthalmology. 2019; 16 (4): 515–21 (In Russ.). https://doi.org/10.18008/1816-5095-2019-4-515-521

32. Ryskulova E.К., Khusnitdinova E.G., Israfilova G.Z., Babushkin A.E. Ointment Ofticipro efficiency in the treatment of bacterial keratitis and corneal ulcers. Point of View. East – West. 2016; 1: 142–4 (In Russ.).

33. Efimova E.L., Brzheskiy V.V. New possibilities of antibiotic therapy for blepharoconjunctivitis in children. Ophthalmology in Russia. 2021; 18 (4): 932–7 (In Russ.). https://doi.org/10.18008/1816-5095-2021-4-932-937

34. Kumar N, Kumar R, Malhotra M, et al. Ophthalmic ointment & formulation: A review. Int J Med Pharm Drug Res. 2024; 8 (2): 47–60. doi: 10.22161/ijmpd.8.2.6